{ "teamId": "06", "lang": "ZH", "region": "美國", "project": "獨創植物細胞生產病毒載體  更低成本、缩短生產週期80%", "company": "Cirsium Biosciences", "contact": { "name": "Jake Connors", "occupation": "Co-founder/CTO", "avatarUrl": "https://expo.taiwan-healthcare.org/data/cht/20241104/20241104iw8pq8.jpeg" }, "logoUrl": "https://expo.taiwan-healthcare.org/data/cht/20241104/2024110450nm8n.jpeg", "mainInvester": "Insight Partners, KDT Ventures, Phi Fund", "established": "2019", "fundingAmount": "7,100萬美元", "annualRevenue": "N/A", "currentFundingRound": "A", "currentFundingAmount": "N/A", "postMoneyValuation": "N/A", "highlights": ["在大型動物模型中已驗證了以植物工廠為基礎的AAV生產，將擴建為佔地 4.8萬平方英尺的設施，包含GMP 生產範圍。", "已將 AAV 基因療法的製造前置時間縮短了 80%，但仍有改善和優化之空間。", "已展現在植物系統中生產其他病毒載體之可行性，成本降 10 倍以上。"], "coreTech": "病毒載體製造平台技術以植物作為生物反應器來生產用於遺傳醫學的高品質 AAV 載體，較傳統製程更有效率，提供最佳成本、純度、產量、可擴展性和安全性。", "coreTechKeywords": ["腺病毒", "AAV製造", "基因療法"], "targetMarket": "病毒載體製造、基因治療製造", "coreProducts": [{ "name": "AAV產製平台", "type": "service", "progress": 0, "countries": "" }], "milestones": ["N/A"] }
